A Money-Back Guarantee for Prescription Drugs


By Sandip Shah and Joe Black

President Trump will soon issue an executive order to lower drug prices. The order likely will encourage federal health agencies to make greater use of "outcomes-based" contracts.

That's great news for patients. These contracts link a drug's price to its effectiveness. If a drug cures or treats patients as advertised, insurers pay the full price. If the drug is less successful than hoped, insurers pay a reduced price or nothing at all.

Freed from the fear of paying for expensive yet ineffective treatments, insurers will be more willing to give patients quick access to advanced drugs while getting assurance that the drugs work. This will improve Americans' health and drive down long-term healthcare spending.

Value-based contracts have become more popular in recent years. A quarter of health plans now have at least one value-based contract -- and 30 percent more are currently negotiating one.

In the past, insurers hesitated to spend money on advanced drugs. To minimize costs, many insurers required patients to try older, cheaper drugs first. Only if those drugs failed would insurers cover the cost of more advanced medications.

Such "step therapy" delays proper treatment for patients.

Value-based contracts negate the need for step therapy. If it turns out drugs aren't as effective as the pharmaceutical companies claim, insurers simply pay the drug companies less. And if the drugs works, patients get better faster, saving healthcare dollars in the long-run.

Value-based contracts also can nudge insurers to cover treatments that they once flat-out denied.

Consider the high-cholesterol drug Repatha. The drug cuts the risk of heart attack by 15 to 20 percent, but it costs a hefty sum. Many insurers didn't want to let patients switch from older, cheaper statins to the more effective Repatha. Unfortunately, this refusal to cover the drug led to 100,000 preventable heart attacks and strokes in 2016.

The drug's manufacturer, Amgen, recently agreed to pay insurers a full refund if eligible patients have a heart attack or stroke while taking Repatha. Health insurer Harvard Pilgrim, which covers 2.7 million people, took the deal. The agreement will no doubt save lives and keep people healthier, lowering long-term spending.

Value-based contracts also help make medicines more effective.

Drugs undergo extensive clinical trials before they're put on the market. But clinical trials are an imperfect tool to measure a drug's effectiveness.

In the real world, patients might pop a pill during dinner -- even though it's supposed to be taken on an empty stomach. Or they might miss a dose.

These differences mean that the drug may perform differently in a real-world setting as compared to a clinical-trial setting. For example, the cancer drug sorafenib prolonged patients' lives by an average of three months during clinical trials. In the real world, though, the drug did not boost life expectancy.

Pharmaceutical companies already track real world data on drug effectiveness. But value-based contracts can guide them to improve physician prescribing directions and patient dosage information, in order to maximize medicines' effectiveness and get the best value for the money spent on the medicine.

Healthcare innovation doesn't always come in the form of a pill. Sometimes, it can be as simple as a new contracting model that expands patients' access to cutting-edge medicines. Pharmaceutical companies are willing to bet on the effectiveness of their drugs. Will insurance companies rise to this challenge?

Sandip Shah is the founder and president of Market Access Solutions, a global market access consultancy, where he develops strategies to optimize patient access to life-changing therapies. Joe Black is a director at Market Access Solutions.

More Resources


03/29/2024
Behind Scenes Stories of Censorship


more info


03/29/2024
Where RFK Jr. Goes From Here


more info


03/29/2024
Will the RFK Factor Make a Difference in 2024?
Robert Kennedy Jr. leads the highest-polling independent presidential ticket in over 30 years

more info


03/29/2024
Democrats May Keep the Senate--With a Little GOP Help
The inexplicable determination of the party's voters to pick unstable provocateurs might be the only path Democrats have to hanging onto their narrow and very much endangered Senate majority.

more info


03/29/2024
You Count Votes Over and Over Until They Add Up Right
By John Kass March 27, 2024 Illinois Gov. J.B. Pritzker-the perpetually frightened rich kid born on third base thinking he hit a triple-has a big fat political problem. He's hosting the Democratic National Convention, his big fat coming out party in Chicago, in August. His fantasy? Becoming president of the United States of America. As he's planning his party, America ... Read More

more info


03/29/2024
The Long Road Back for the Port of Baltimore
For the moment, Maryland officials are focused on crisis management.

more info


03/29/2024
Enough Already
City leaders keep searching for the root cause of crime-they should look in the mirror.

more info


03/28/2024
The Democrats' Abundance Problem Revisited
Last week, I started revisiting my "Three Point Plan to Fix the Democrats and Their Coalition" from October of 2022. A brisk tour of the polling and political data suggested the Democrats are still in need of serious reform and that the three point plan is as relevant as ever. Here's the very short version of the plan:

more info


03/28/2024
Are Democrats Still Stuck With Biden?
Voters don't think much of the president but also remain wary of the obvious replacement.

more info


03/28/2024
What the Polls Say: RFK Jr. Hurting Biden, Helping Trump
In October, when Robert F. Kennedy Jr. abandoned his primary challenge to Joe Biden and instead launched an independent candidacy, the initial conventional wisdom was that he might hurt Donald Trump more than Biden.

more info


03/28/2024
The Twilight of the Republican 'McLeadership'
The Trump team is steadily purging the Republican leadership of holdovers from past decades. The departure of McCarthy, McDaniel, and McConnell is part of exorcising the legacy of a more important Mc whose influence is still felt in the U.S. Senate: John McCain.

more info


03/28/2024
The Funniest Media Story of the Year?
The following three things were obvious before MSNBC puked on itself in its public divorce with former RNC chief Ronna McDaniel, but aren't we glad the network didn't notice? More later, but briefly:

more info


03/28/2024
Abridging, Not Coercing, Is First Amendment's Yardstick
Under the First Amendment, the government may not abridge the freedom of speech, whether that abridging is done by coercing internet platforms or by getting them to cooperate in government efforts to censor the public.

more info


03/28/2024
Trade Cheaters Are Killing Aluminum Industry Jobs
Aluminum industry workers stand ready to do their part to move the nation forward. They just need the federal government to enforce trade laws.

more info


03/28/2024
It's Time for an Immigration Moratorium
An effective freeze on immigration could revitalize our national culture, politics, and economy before it's too late.

more info



Custom Search

More Politics Articles:

Related Articles

Pelosi's Drug Plan Would Kill Innovation -- and Hope


"Help is on the way." That's what House Speaker Nancy Pelosi told American patients when she unveiled her sweeping plan to lower drug prices.

Solving the Looming Superbug Crisis Will Require Bold Action From Congress


Antimicrobial resistance killed upwards of 160,000 Americans in 2010. More and more infections are becoming resistant to antibiotics and antifungals — and while Americans know this is a growing problem, few know how bad it already is.

One Nation Under God?


"I had no idea how critical religion is to the functioning of democracy." So said a Marxist economist from China conversing with Harvard Professor, Clayton Christensen.

The Art of the Budget Deal: White House and Congress Cooperate?


Last week, President Donald Trump and House Speaker Nancy Pelosi announced a two-year budget deal that suspends the debt ceiling, and will raise federal spending $320 billion over amounts agreed to during the Obama years.

Showdown with the Ayatollahs: A Dangerous Situation


Yesterday, President Donald Trump imposed more economic sanctions on Iran. In response, Iranian officials denounced the sanctions. Does diplomacy have a chance in this situation? Or is war inevitable?

AOC's Ravings Against Billionaires


"No one ever makes a billion dollars. You take a billion dollars."

House Drug Bill Dooms Medical Research


House lawmakers recently voted to pass the "Lower Drug Costs Now Act," which would enable government officials to set the price of lifesaving medicines. The bill would reduce pharmaceutical companies' revenues by a staggering $1 trillion over the coming decade.

To Boost the Economy, Fight Chronic Disease


To understand the health of an economy, look at the health of those who participate in it.

Animal Rights Groups Choose Coronavirus Over Your Safety


Top U.S. health officials recently delivered a sobering message: Americans must prepare for the inevitable spread of the coronavirus within the United States. So far in the U.S., 11 people have died. The virus has claimed the lives of more than 3,200 people and infected over 95,000 worldwide.

How To Draw On The Power Of Perseverance During COVID-19


People's ability to keep up their spirits is being put to the test during the COVID-19 pandemic. Health concerns, job concerns, and disruptions to day-to-day routines have combined to create a challenging situation for Americans and for people throughout the world.

Trump's "Buy America" Plan Will Backfire


In response to the ongoing coronavirus pandemic, the Trump administration wants to quarantine American manufacturing. At any time now, the president could sign an executive order aimed at returning the pharmaceutical supply chain to the United States.

Exercising Bayh-Dole March-in Rights Would Handicap COVID-19 Innovation


Scientists across America are working hard to develop treatments for and vaccines against COVID-19. Unfortunately, several activist groups are making their jobs harder.

Academic Research Can't End the Pandemic Without Private Backing


Scientists at Yale University and scores more research institutions nationwide are working around the clock to identify potential avenues of diagnosing, preventing, and treating COVID-19. Many of these projects are backed by the federal government's National Institutes of Health. Any one of them could lead to a game-changing insight that helps end this pandemic.

Natural Gas Will Power Our Economic Recovery


After months of sheltering in place, Americans are finally returning to their favorite restaurants, stores, and barbershops.

"All the News That's Fit to Print," As Long As It Promotes a Progressive Agenda


One hundred and 23 years later, the New York Times still boasts of its alleged objectivity with the phrase "All the News That's Fit to Print" located on the upper left-hand corner of its front page. The slogan was the idea of the paper's owner Adolph S. Ochs in 1897. He meant it as "a declaration of the newspaper's intention to report the news impartially," according to the language arts Website ReadWriteThink.